Entinostat: Phase I/II started

Syndax said investigators at the M.D. Anderson Cancer Center began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate oral entinostat given on days 1 and 15 in combination with once-daily Tykerb lapatinib in a 28-day cycle in about 70 patients previously treated with Herceptin trastuzumab. Data from the Phase I portion of the trial are expected as early as June. ...